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Hydroxmethylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors (statins) lower serum cholesterol but
exhibit pleiotropic biological effects that are difficult to ascribe solely to cholesterol depletion. Here, we
investigated the effect of lovastatin on protein prenylation and cell signaling. We show that high concentrations
(50 M) of lovastatin inhibit Ras, Rho, and Rap prenylation but that therapeutic levels of lovastatin (50 nM
to 500 nM) do not. In contrast, depletion of cellular cholesterol by therapeutic levels of lovastatin increased Ras
GTP loading and mitogen-activated protein kinase (MAPK) activation in human umbilical vein endothelial
cells and rodent fibroblasts. Elevated Ras signaling was not seen in statin-treated cells if cholesterol levels were
maintained by supplementation. Activation of Ras-MAPK signaling was a consequence of, and dependent on,
activation of phospholipase D2 (PLD2). Expression of dominant interfering PLD2 or biochemical inhibition of
PLD2 abrogated Ras and MAPK activation induced by lovastatin. In contrast, ectopic expression of wild-type
PLD2 enhanced Ras and MAPK activation in response to therapeutic levels of lovastatin. Statin-induced
cholesterol depletion also modestly activated the epidermal growth factor receptor (EGFR), resulting in
downregulation of EGFR expression. These results suggest that statins modulate key cell signaling pathways
as a direct consequence of cholesterol depletion and identify the EGFR-PLD2-Ras-MAPK axis as an important
statin target.
Hydroxmethylglutaryl (HMG)-coenzyme A (CoA) reduc-
tase inhibitors (statins) are widely used for the treatment of
hypercholesterolemia (39). These drugs block the conversion
of HMG-CoA to mevalonate, a rate-limiting step in the cho-
lesterol biosynthesis pathway (15). In addition to the choles-
terol-lowering effect, there is extensive evidence for additional
clinical effects. Statins improve endothelial function, promote
vascular relaxation, and inhibit platelet aggregation in part by
driving increased synthesis of nitric oxide (NO) (36). Statins
therefore correct the reduced synthesis, release, and activity of
endothelium-derived NO observed in hypercholesterolemic
patients (39). Statins also promote atherosclerotic plaque sta-
bility (58), have anti-inflammatory effects (3, 60), and are as-
sociated with a reduced risk of Alzheimer’s disease (39). Nev-
ertheless, it has been difficult to mechanistically link many of
these beneficial clinical effects directly to reduced cellular and
serum cholesterol levels.
One class of signaling molecules that has been identified as
putative cholesterol-independent targets of statin action are pre-
nylated small GTPases (16, 17, 39, 42). Ras and Rho GTPases act
as molecular switches to regulate cell proliferation, differentia-
tion, apoptosis, and cytoskeletal reorganization (26, 31). The bi-
ological activity of these GTPases requires farnesylation or gera-
nylgeranylation of C-terminal CAAX motifs (where C is Cys, A is
aliphatic amino acid, and X is Ser or Met in Ras or Leu in Rho)
(27). High concentrations of statins have long been known to
block Ras and Rho prenylation (27) by blocking production of
mevalonate, a precursor of farnesyl and geranylgeranyl pyrophos-
phates used for protein prenylation (15). However, it is unclear
whether the therapeutic levels of statins that are achieved in
patients are sufficiently high to do so (38, 56).
The plasma membrane is a complex, dynamic, and laterally
heterogeneous structure, which imposes nonrandom distribu-
tions on proteins across different types of transient, nanoscale
domains (23, 55, 59). The assembly of signaling proteins, in-
cluding Ras GTPases and epidermal growth factor receptor
(EGFR), into specific nanodomains and nanoclusters is essen-
tial for high-fidelity signal transmission (2, 30, 50, 52, 59). The
spatial organization of signaling complexes on the plasma
membrane is driven by lipid-lipid, protein-lipid, and protein-
protein interactions. In consequence, perturbation of the lipid
structure of the plasma membrane, as occurs following choles-
terol depletion, can directly dysregulate signal transduction
(12, 26, 46, 50, 51, 54). Here, we investigate whether Ras
prenylation is affected by therapeutic levels of lovastatin and
explore more broadly the effect of statins on Ras signal trans-
duction. We identify a novel effect of statins on Ras signaling
that is directly related to cholesterol depletion and involves
remodeling of the lipid structure of the plasma membrane.
MATERIALS AND METHODS
Plasmids and reagents. Green fluorescent protein (GFP)-tagged wild-type
(WT) murine phospholipase D2 (mPLD2 WT) and GFP-tagged mPLD2 K758R,
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kindly provided by Mike Frohman (Stony Brook University, Stony Brook, NY),
were subcloned into the pEF6/V5-His-TOPO plasmid (Invitrogen, Australia).
Antibodies against extracellular signal-regulated kinase 2 (ERK2) (C-14) (no.
sc-521), K-Ras2B (C-19) (no. sc-521), H-Ras (F235) (no. sc-29), and N-Ras
(F155) (no. sc-31) were obtained from Santa Cruz Biotechnology (CA). Mono-
clonal antibodies anti-caveolin-1 (no. 610406), anti-Ras (no. 610001), and anti-
Rho (no. 610990) were obtained from BD Transduction Laboratories (Lexing-
ton, KY). Rabbit phospho-p44/42 mitogen-activated protein kinase (MAPK)
(ERK1/2) (Thr202/Tyr204) antibody (no. 9101), mouse phospho-p44/42 MAPK
(ERK1/2) (E10) antibody (no. 9106), rabbit phospho-Akt (pAkt) (Ser473) anti-
body (no. 9271), rabbit Akt antibody (no. 9272), mouse anti-phospho-EGF
receptor (Y1068) antibody (no. 2236), rabbit total EGF receptor antibody (no.
2232), and rabbit Rap1A/B (26B4) antibody (no. 2399) were from Cell Signaling
Technology (Beverly, MA). Monoclonal anti-GFP (no. 11814460001) was from
Roche. Tertiary butanol (no. 360538), lipoprotein-deficient serum (LPDS)
(S5394), low-density lipoprotein (LDL) from human plasma (LDL cholesterol
[LDL-C]) (L7914), lovastatin (M2147), and mevalonate (M4667) were pur-
chased from Sigma Aldrich.
Preparation of active lovastatin. Lovastatin was converted to an active form as
described previously (35). Briefly, inactive lovastatin was dissolved in warm
(55°C) ethanol, to which 0.6 M NaOH and H2O were added. The solution was
incubated at room temperate for 30 min to complete the opening of the beta-
lactone ring. The final lovastatin solution was adjusted to pH 8.0 with HCl and
stored as a 10 mM stock at 20°C.
Cell culture. Baby hamster kidney (BHK) cells were maintained in Dulbecco’s
modified Eagle medium (DMEM) (Gibco) supplemented with 10% donor calf
serum (DCS) and 2 mM L-glutamine. Human umbilical vein endothelial cells
(HUVECs) (CRL 1730; ATCC) were maintained in Ham’s F-12K medium
(Gibco) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 0.1
mg/ml heparin (Sigma Aldrich), and 0.03 mg/ml endothelial cell growth supple-
ment (ECGS) (Sigma Aldrich). The passage numbers of HUVECs used in this
study were 3 and 4. All cell lines were grown at 37°C at 5% CO2. For cholesterol
depletion experiments, DCS or FCS was replaced with LPDS, which was sup-
plemented where indicated with purified LDL-C. To generate stable cell lines,
BHK cells were transiently transfected with GFP-mPLD2 WT or GFP-mPLD2
K758R using Lipofectamine reagent (Invitrogen) according to the manufactur-
er’s instructions. Following an overnight incubation, cells expressing the trans-
fected protein were sorted using fluorescence-activated cell sorting (FACS) and
maintained in BHK medium containing 1 mg/ml G418 (Geneticin; Sigma Al-
drich).
Cholesterol assays. Total cellular cholesterol levels were measured using an
Amplex Red cholesterol assay kit (A12216; Invitrogen) according to the manu-
facturer’s instructions.
Subcellular fractionation and Ras processing assays. Subcellular fractionation
into S100 and P100 fractions after hypotonic lysis was carried out as described
previously (54). Triton X-114 (TX-114) partitioning was carried out exactly as
described previously (22, 25). Lysates of cells were prepared in ice-cold, precon-
densed 1% TX-114 (dissolved in 25 mM Tris-Cl [pH 7.5], 150 mM NaCl), cleared
by centrifugation, and warmed for 2 min at 37°C. Detergent and aqueous phases,
containing hydrophobic and hydrophilic proteins, respectively, were separated by
centrifugation and analyzed by quantitative Western blotting.
Western blotting. Cells were washed in cold phosphate-buffered saline (PBS)
and subjected to detergent lysis in a buffer containing 50 mM Tris (pH 7.5), 75
mM NaCl, 25 mM NaF, 5 mM MgCl2, 5 mM EGTA, 1 mM dithiothreitol, 100
M NaVO4, 1% Nonidet P40 plus protease inhibitors. SDS-PAGE and immu-
noblotting with the specified antibody were performed using 20 g of each lysate.
Signal was detected by enhanced chemiluminescence (SuperSignal; Pierce,
Thermo Fisher Scientific, Rockford, IL) and imaged by FluorChemQ (Alpha
Inotech, San Leandro, CA). Quantification of intensities was performed using
FluorChemQ software.
Ras RBD pulldown assay. Ras-GTP levels were measured in a glutathione
S-transferase (GST)-Ras binding domain (RBD) pulldown assay as described
previously (54). Samples were analyzed by quantitative Western immunoblotting
using pan-Ras or Ras isoform-specific antibodies.
PLD assays. To assay the requirement for phospholipase D (PLD) activity
cells were incubated for 4 h in 1% (vol/vol) n-butanol or t-butanol. PLD normally
carries out a transphosphatidylation reaction using water as an acceptor to
generate phosphatidic acid (PA). The enzyme, however, has a strong preference
(1,000-fold) for primary alcohols over water, leading to the generation of phos-
phatidyl alcohols. The generation of phosphatidic acid by PLD is therefore
efficiently blocked in the presence of low concentrations of the primary alcohol
n-butanol but is unaffected in the presence of the tertiary alcohol, t-butanol (34).
Metabolic labeling and phosphatidic acid assay by TLC. A modified version of
a previously described method (63) was used. After 32 h of lovastatin treatment,
BHK cells were labeled with [3H]palmitate (2 mCi/ml) for a further 14 h in the
continued presence of lovastatin. The labeling medium was then replaced with
fresh medium containing lovastatin for 2 h. Cells were then harvested with
ice-cold methanol and vortexed with chloroform. After incubation at room tem-
perature for 15 min, H2O was added, followed by centrifugation. Twenty micro-
liters of the lower organic phase was used for scintillation counting to estimate
the total labeled phospholipids. The remainder of the organic phase was dried by
vacuum centrifugation and resuspended in chloroform-methanol (19:1) for spot-
ting onto thin-layer chromatography (TLC) plates (no. 2855-821; Whatman
LK5D). The plate was developed using the upper phase of a mixture of ethyla-
cetate-2,2,4 trimethylpentane (isooctane)-acetic acid-H2O (110:50:20:100). The
position of PA was identified by the synthetic 3,4-dihydroxyphenylalanine
(DOPA) standard (840875C; Avanti Polar Lipids, Inc.) after iodine staining. The
plate treated with Enhance spray (6NE970C; PerkinElmer) was then incubated
with an X-ray film at 80°C for 48 h, and the bands corresponding to the
phosphatidic acid standard were cut out for scintillation counting.
RESULTS
Effects of lovastatin on cellular cholesterol levels. The clin-
ical effect of statins in reducing cellular cholesterol is mediated
by two mechanisms. First, statins have a major site of action in
the liver, where the drug is subject to extensive first-pass me-
tabolism. Reduction in cellular cholesterol synthesis elevates
hepatocyte expression of the LDL receptor, leading to in-
creased clearance of plasma LDL by the liver and a reduction
in circulating LDL cholesterol (LDL-C) levels. Current clinical
guidelines advocate statin dose escalation to reduce LDL-C
levels to 70 mg/dl in high-risk patients and 100 mg/dl in all
hypercholesterolemic patients (20, 57). Second, statins can also
directly reduce endogenous cholesterol synthesis in all extra-
hepatic tissues.
To explore the signaling effects of statin-induced cholesterol
depletion, BHK cells and HUVECs were chosen as model
fibroblast and endothelial cell lines, respectively. Cells were
cultured in medium containing 10% lipoprotein-deficient se-
rum (LPDS) to mimic the reduced LDL-C level induced by
statins. The plasma lovastatin levels 6 h after therapeutic doses
of 40 to 200 mg are in the range of 50 to 250 nM (38); however,
given that higher doses of statins may be prescribed, we eval-
uated cells treated with lovastatin in a concentration range of
50 to 500 nM to fully capture likely therapeutic levels.
Figure 1a and c show that a major reduction in cellular
cholesterol is achieved by growth in LPDS (reflecting the he-
patic effect of statin in reducing plasma LDL-C levels), but this
is modestly supplemented by a direct effect on de novo synthe-
sis within the target cell, leading to a further decline in cellular
cholesterol. The cholesterol content of LPDS is very low,
equivalent to 3 mg/dl of LDL-C. Therefore, to more pre-
cisely model the clinical situation, we supplemented LPDS
with purified human LDL-C to give levels of 240 mg/dl (high
cholesterol level) and 100 mg/dl (normal) and reassayed cho-
lesterol levels. Figure 1b and d show that BHK cells and
HUVECs cultured in LPDS plus 240 mg/dl LDL-C closely
mirrored the control cells grown in DCS and FCS, respectively,
in exhibiting a high basal cellular cholesterol level with no
significant decrease in the presence of statin. In contrast, cells
cultured in LPDS plus 100 mg/dl LDL-C had significantly
lower basal cholesterol levels than cells grown in DCS or LPDS
plus LDL-C 240 mg/dl and showed a further 15 to 18% fall on
culture in 300 to 500 nM lovastatin. In sum, Fig. 1a to d show
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that an effect of statin on de novo cholesterol synthesis is
observed only if the exogenous supply of cholesterol is sub-
stantially reduced by growth in LPDS with low LDL-C levels.
Effect of therapeutic levels of lovastatin on the prenylation
of Ras and Rho GTPases. High concentrations of statins can
prevent protein prenylation (37, 39, 53). To determine whether
therapeutic levels of lovastatin inhibit prenylation of Ras and
Rho GTPases, we examined steady-state levels of prenylated
and nonprenylated Ras and Rho family proteins in lovastatin-
treated cells by use of a Triton X-114 partitioning assay. This
assay separates prenylated proteins from unprenylated pro-
teins based on the increased hydrophobicity due to the farnesyl
or geranylgeranyl anchor (22, 25, 27, 29). In control cells, the
majority of endogenous Ras (farnesylated [6, 27]) and endog-
enous Rap1A/B (geranylgeranylated [4]) partitioned into the
Triton X-114 detergent phase (Fig. 1e), and a substantial frac-
tion of endogenous Rho (geranylgeranylated [1]) also parti-
tioned into the detergent phase. The detergent fraction is
lower because of the interaction of geranylgeranylated Rho
with the chaperone protein RhoGDI (43). At all therapeutic
FIG. 1. Effect of therapeutic levels of lovastatin on cellular cholesterol and Ras prenylation. BHK cells (a) and HUVECs (c) were cultured in
growth medium containing 10% DCS, 10% FCS, or 10% LPDS in the presence of lovastatin for 48 h. BHK cells (b) and HUVECs (d) were
cultured in growth medium containing 10% LPDS supplemented with 100 or 240 mg/dl purified LDL-C. Total cellular cholesterol levels were
measured. The graphs show means  standard errors of the means (SEM) for 3 independent experiments. Differences between lovastatin-
untreated and lovastatin-treated cells under each culture condition in panels a to d were assessed using one-way analysis-of-variance (ANOVA)
tests, and significant differences are indicated (*, P  0.05). (e) HUVECs were treated with various concentrations of lovastatin in the presence
of 10% LPDS for 48 h. Control cells were cultured in standard growth medium containing 10% FCS. Cells were lysed in 1% Triton X-114 and
lysates separated into detergent-enriched (Det.) and aqueous (Aq) phases by warming. After separation of the two phases by centrifugation, a 1
volume of the detergent-enriched phase (20 l) containing hydrophobic proteins and a 2 volume of the aqueous phase (40 l) containing
hydrophilic proteins were blotted with an anti-pan Ras, anti-Rho, or anti-Rap1A/B antibody. A representative blot and mean percentages of the
detergent fraction for 3 independent experiments are shown.
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levels of lovastatin, the detergent partitioning of endogenous
Ras, Rap, and Rho proteins was nearly identical to that in
control cells, suggesting that protein prenylation was not af-
fected at these concentrations. In the presence 50 M lova-
statin, however, the partitioning of endogenous Ras, Rho, and
Rap into the aqueous phase of Triton X-114 significantly in-
creased. The increased aqueous partitioning of Ras, Rho, and
Rap was reversed when cells were supplemented with meval-
onate, the direct product of HMG-CoA reductase. Subcellular
fractionation also showed no reduction in binding of Ras to
cellular membranes in cells grown in lovastatin concentrations
of 500 nM (data not shown). Taken together, these results
show that therapeutic levels of lovastatin have no significant
effects on Ras, Rho, or Rap prenylation.
Cholesterol depletion by lovastatin activates Ras signaling.
As therapeutic levels of lovastatin do not affect Ras prenyla-
tion, we investigated other mechanisms whereby lovastatin
may modulate cellular signaling. We first examined activation
of ERK and Akt as general screens for Ras signal output. Cells
were treated with a range of concentrations of lovastatin in
10% LPDS for 48 h, and lysates were immunoblotted for phos-
pho-ERK (ppERK) and phospho-Akt (pAkt). Control cells
were grown in DCS or FCS with the same range of concentra-
tions of lovastatin. In HUVECs and BHK cells, therapeutic
levels of lovastatin in LPDS significantly increased the basal
level of mitogen-activated protein kinase (MAPK) activity and
reduced basal levels of pAkt (Fig. 2). A similar effect was also
seen in cells grown in lovastatin in LPDS plus 100 mg/dl
LDL-C (data not shown). Pooling the data sets from Fig. 1a to
d with those of Fig. 2a and b reveals a striking inverse linear
relationship between basal ppERK levels and cellular choles-
terol content in both BHK cells and HUVECs (Fig. 2c and d).
FIG. 2. Therapeutic levels of lovastatin modulate ERK and Akt activation. BHK cells (a and e) and HUVECs (b and f) were cultured in growth
medium containing 10% DCS, 10% FCS, or 10% LPDS in the presence of lovastatin for 48 h. Cell lysates were assayed for ppERK or pAkt (S473)
using phospho-specific antibodies and quantitative immunoblotting. The graphs show mean levels of ppERK or pAkt, relative to levels in cells
grown in 10% DCS or FCS without lovastatin,  SEM for 3 independent experiments. Differences between lovastatin-untreated and lovastatin-
treated cells under each culture condition were assessed using one-way ANOVA tests, and significant differences are indicated (*, P  0.05). (c
and d) Total cellular cholesterol levels in Fig. 1 were plotted against the corresponding mean ppERK levels shown in panels a and b. The line was
fitted by linear regression.
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To determine whether the increased MAPK activity was
dependent on Ras activity, we directly measured Ras-GTP
levels. These results showed that cholesterol depletion by ther-
apeutic levels of lovastatin significantly activated Ras (Fig. 3a).
Further analysis showed that all three Ras isoforms, H-, N-,
and K-Ras, were activated (Fig. 3b). Similar effects of lova-
statin were observed on acute Ras activation in response to
serum stimulation (data not shown). The addition of water-
soluble cholesterol to cells treated with therapeutic levels of
lovastatin in 10% LPDS returned the elevated Ras GTP levels
to control values (Fig. 3a). Similarly, BHK cells grown in DCS
plus lovastatin, which did not show any elevation of MAPK
activity or change in cellular cholesterol levels, did not exhibit
elevated levels of Ras-GTP (Fig. 2 and data not shown). Taken
together, these data suggest that elevated MAPK activity due
to lovastatin-induced cholesterol depletion is a direct conse-
quence of enhanced Ras activity and that activation of the
Ras-MAPK pathway in cells chronically exposed to lovastatin
correlates closely with cholesterol depletion.
Lovastatin-induced activation of Ras signaling is mediated
by PLD2. We have shown that cholesterol depletion by thera-
peutic levels of lovastatin enhances Ras GTP loading, with a
concomitant increase in ERK activation. Activation of the Ras-
MAPK cascade could be at the level of receptors, such as the
EGF receptor (EGFR), that couple to Ras, or the activity of
RasGEFs or RasGAPs could be stimulated or inhibited, re-
spectively. To discriminate between these possibilities, we ex-
amined the levels of EGFR and activated EGFR, monitored as
Y1068 phospho-EGFR (2), in cells grown in LPDS with lova-
statin. Figure 4a shows that total EGFR levels were signifi-
cantly decreased after 48 h of growth in LPDS with lovastatin;
however, the specific activity of the EGFR was simultaneously
increased (Fig. 4b). In contrast, no change in EGFR levels was
seen in cells grown in lovastatin and DCS rather than LPDS
(Fig. 4c), conditions that do not change cellular cholesterol
levels. Similar results were observed in HUVECs (data not
shown).
Phospholipase D2 (PLD2), which is localized predominantly
to the plasma membrane (10, 33, 34), hydrolyzes phosphati-
dylcholine to phosphatidic acid (34). Recent studies have
shown that phosphatidic acid generated by PLD2 is an up-
stream regulator of Ras activation in EGF- and T-cell recep-
tor-regulated signaling pathways (24, 45, 65). Following EGFR
stimulation, phosphatidic acid produced by PLD2 recruits Sos
to the plasma membrane, stimulating Ras activation. We
therefore tested whether cholesterol depletion induced by lo-
vastatin stimulates the catalytic activity of PLD2, leading to
Ras and MAPK activation. BHK cells were treated with lova-
statin for 44 h and then incubated in 1% primary (n)-butanol
or tertiary (t)-butanol. Previous work has shown that n-butanol
inhibits the production of phosphatidic acid by PLD but that
t-butanol does not (45). Treatment with n- or t-butanol had no
effect on Ras-GTP or ppERK levels in control cells. However,
the elevated Ras-GTP and ppERK levels in cholesterol-de-
pleted cells were significantly reduced after incubation in n-
butanol but not after incubation in t-butanol (Fig. 5a and b).
FIG. 3. Activation of Ras signaling by lovastatin is a consequence of cholesterol depletion. (a) BHK cells treated with lovastatin in the presence
of 10% LPDS for 48 h were incubated with 25 M water-soluble free cholesterol (CHOL) or vehicle (CON) at 37°C for 20 min and harvested.
Total Ras-GTP levels were measured in an RBD pulldown assay and compared to the level for cells grown in DCS. The graph shows mean fold
increases in Ras-GTP levels  SEM for 3 independent experiments. Differences between lovastatin-treated and control cells in the presence and
absence of free cholesterol were assessed using one-way ANOVA tests. Significant differences are indicated (*, P  0.05). A representative blot
is shown. (b) BHK cells were treated with various concentrations of lovastatin in the presence of 10% LPDS for 48 h. Control cells were cultured
in standard growth medium containing 10% DCS. H-, N-, and K-Ras-GTP loadings were measured using an RBD pulldown assay. A blot
representative of 4 (H- and N-Ras) or 3 (K-Ras) independent experiments is shown.
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If PLD activity is elevated as suggested by the data in Fig. 5,
cells grown in LPDS and lovastatin would be expected to have
elevated plasma membrane levels of phosphatidic acid com-
pared to cells grown under control conditions. We first mea-
sured total cellular phosphatidic acid levels by metabolic label-
ing and thin-layer chromatography (63). Figure 6a shows that
there is a dose-dependent increase in phosphatidic acid levels
in cells grown in LPDS and increasing doses of lovastatin. To
verify that plasma membrane levels of phosphatidic acid are
specifically increased by lovastatin-induced cholesterol deple-
tion, we made use of a previously characterized, fluorescent-
tagged phosphatidic acid-binding probe (mGFP-NES-Spo20).
Electron microscopy (EM) analysis of intact plasma membrane
sheets prepared from BHK cells expressing mGFP-NES-Spo20
showed a significantly increased level of anti-GFP immunogold
labeling after treatment for 48 h in lovastatin and LPDS (Fig.
6b). Increased phosphatidic acid production on the plasma
membrane was further confirmed by increased fluorescence
resonance energy transfer (FRET) between mGFP-NES-
Spo20 and mRFP-NES-Spo20 in cells grown in lovastatin and
LPDS (Fig. 6c).
Lovastatin-induced activations of PLD2 and EGFR are in-
dependent events. PLD2 is a downstream effector of the
EGFR (45, 65); however, PLD2 activation also enhances
EGFR clustering (2), which in turn might potentiate EGFR
activation. We therefore explored the interplay between
EGFR activation and PLD2 activation in cholesterol-depleted
cells. Figure 7a shows that EGFR downregulation in lovasta-
FIG. 4. EGF receptor expression is downregulated by lovastatin treatment. BHK cells were treated with lovastatin in the presence of 10%
LPDS for 48 h. Control cells were cultured in standard growth medium containing 10% DCS. Total EGFR and phospho-EGFR (Y1068) levels
were measured by quantitative immunoblotting. The graph in panel a shows mean EGFR and pEGFR levels SEM relative to levels in cells grown
in control medium. An immunoblot representative of 3 independent experiments is also shown. ERK2 levels are used as a loading control. The
specific activity of the EGFR (b) was estimated as the normalized ratio of phospho-EGFR to total EGFR using values obtained from panel a. For
panels a and b, differences between lovastatin-treated and control cells were assessed using one-way ANOVA tests. Significant differences are
indicated (*, P  0.05; **, P  0.01). (c) BHK cells were cultured in growth medium containing 10% DCS or 10% LPDS in the presence of
lovastatin. Note that these growth conditions replicate those in Fig. 1a, where the presence of DCS maintains normal cell cholesterol levels in the
presence of lovastatin. Total EGFR levels were measured by quantitative immunoblotting. The graph shows mean EGFR levels  SEM relative
to levels in cells grown in DCS. Differences between cells cultured in DCS and LPDS at each concentration of lovastatin were assessed using
two-tailed t tests. Significant differences are indicated (*, P  0.05; **, P  0.01). An immunoblot representative of 3 independent experiments
is also shown. ERK2 levels are used as a loading control.
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tin-treated cells was completely reversed in the presence of the
EGFR inhibitor, AG1478, whereas ERK activation (Fig. 7c)
and Ras activation (Fig. 7e) were unaffected by AG1478.
EGFR and ppERK levels in control cells grown in DCS and
lovastatin were also unaffected by AG1478 (Fig. 7b and d).
To further explore the specific role of PLD2 in Ras activa-
tion mediated by lovastatin-induced cholesterol depletion, we
studied the effect of ectopically expressing wild-type (WT)
murine PLD2 (mPLD2) or a catalytically inactive mutant
(K758R) of PLD2 that acts as a dominant interfering mutant
(65). BHK cells stably expressing GFP-mPLD2 WT or GFP-
mPLD2 K758R were treated with lovastatin for 48 h, and the
levels of Ras-GTP and ppERK were measured. Figure 8a
shows that expression of mPLD2 WT significantly enhanced,
and that expression of mPLD2 K758R blocked, Ras activation
in response to lovastatin treatment. These changes in Ras-GTP
levels were reflected in similar effects on MAPK activation
measured as ppERK (Fig. 8b). Expression of mPLD2 K758R
also abrogated the inhibition of Akt induced by lovastatin but
did not prevent EGFR downregulation induced by lovastatin
treatment (Fig. 8c and d).
Taken together, these results suggest that cholesterol deple-
tion by lovastatin enhances the catalytic activity of PLD2, pro-
moting phosphatidic acid production, which leads to Ras/
MAPK activation and Akt inhibition. We further conclude that
activation of PLD2 leading in turn to activation of Ras and the
MAPK cascade and low-level activation of the EGFR leading
to downregulation of EGFR levels are likely independent ef-
fects of statin-induced cholesterol depletion.
DISCUSSION
In this report, we examined to what extent Ras prenylation
is affected by therapeutic levels of lovastatin and explored
more broadly the effect of statins on Ras signal transduction.
We show that clinically relevant concentrations of lovastatin
(50 to 500 nM), which significantly lower total cellular choles-
terol levels, do not affect Ras, Rap, or Rho prenylation. Cells
preferentially use farnesyl-pyrophosphate for protein prenyla-
tion over cholesterol biosynthesis, as evidenced by an 50%
inhibitory concentration (IC50) of 2.6 M lovastatin for Ras
farnesylation and an IC50 of 9.8 nM lovastatin for cholesterol
biosynthesis (56). Thus, while nonphysiological, high-lovastatin
concentrations (10 to 50 M) inhibit Ras signaling by blocking
farnesylation and membrane binding (27), this is not a mech-
anism that is likely to be clinically relevant. In contrast, we
observed that cholesterol depletion induced by therapeutic
levels of lovastatin enhanced Ras activation and stimulated
MAPK activity. Several lines of evidence implicate PLD2 as
the critical target of lovastatin action in the Ras signaling
pathway: a chemical inhibitor of PLD and a dominant inter-
fering mutant of PLD2 both blocked Ras/MAPK activation
induced by lovastatin, whereas ectopic expression of wild-type
PLD2 enhanced Ras/MAPK activation induced by lovastatin.
FIG. 5. PLD activity is required for Ras and ERK activation in response to cholesterol depletion. BHK cells were treated with lovastatin for
48 h in the presence of 10% LPDS. Control cells were cultured in 10% DCS. For the final 4 h of incubation, n-butanol (BtOH) or t-BtOH was
added to the growth medium to give a final concentration of 1% (vol/vol). Ras-GTP levels were measured using an RBD pulldown assay (a) and
ppERK levels measured by quantitative immunoblotting (b). A representative blot for each experiment is shown, with total Ras and ERK2 used
as loading controls. Growth in n-butanol inhibits phosphatidic acid production by PLD, whereas growth in t-butanol does not (Materials and
Methods). The graphs show mean levels  SEM for 3 independent experiments. Differences between lovastatin-treated and control cells grown
in n-BtOH or t-BtOH were assessed using one-way ANOVA tests. Significant differences are indicated (*, P 0.05; **, P 0.01; ***, P 0.001).
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Previous work has shown that PLD2 may be associated with
cholesterol-dependent plasma membrane nanodomains, com-
monly called lipid rafts (10), and that cholesterol depletion
leads to PLD2 activation (11). Collecting these data together
with the new results presented in this paper, we propose that
PLD2 is a cholesterol-sensitive regulator of the Ras/MAPK
signaling pathway.
The exact mechanism by which cholesterol depletion acti-
vates PLD2 is not clear, but the subsequent molecular mech-
anism that leads to Ras activation has been elucidated. Acti-
vation of PLD2 remodels the lipid bilayer by hydrolyzing
phosphatidylcholine to phosphatidic acid, and this drives re-
cruitment of the Ras exchange factor Sos by direct binding of
the Sos PH domain to phosphatidic acid (65). On the
nanoscale, therefore, activated PLD2 will drive colocalization
of plasma membrane-recruited Sos and plasma membrane-
localized Ras, promoting Ras GTP loading (24). Protein- and
lipid-based sorting of Ras proteins into nanoclusters on the
plasma membrane is critically important for Ras signaling (28,
50, 51). Interestingly, neither K-Ras-GTP nanoclusters nor
H-Ras-GTP nanoclusters to which Raf/MEK and ERK are
specifically recruited from the cytosol for activation require
cholesterol to form (49–52, 59). Cholesterol depletion induced
by lovastatin therefore facilitates Ras GTP loading but does
not impair the formation or assembly of active Ras-GTP sig-
naling nanoclusters, resulting in increased MAPK output.
Acute cholesterol depletion as a consequence of treating cells
with methyl--cyclodextrin (MCD) also increases ERK phos-
phorylation by inactivating an ERK-specific phosphatase (61).
Potential differences between acute MCD and chronic lova-
statin treatment on cell signaling remain to be further investi-
gated but indicate that cholesterol depletion regulates the Ras/
MAPK pathway at multiple levels.
Statin-induced cholesterol depletion also resulted in down-
regulation of EGFR levels in both HUVECs and BHK cells.
Furthermore, this downregulation correlated with low-level
activation of the EGFR and was completely abrogated by
treating statin-exposed cells with the EGFR kinase inhibitor,
AG1478. Taken together, these results indicate that downregu-
lation of EGFR levels is a direct consequence of statin-induced
EGFR activation. We have shown recently that activation of
PLD2 drives increased EGFR clustering but not increased
EGFR activation (2). Consistent with these results, inhibition
of PLD2 activity did not prevent statin-induced EGFR activa-
tion or downregulation of EGFR levels. Interestingly, blocking
EGFR activity with AG1478 had minimal effect on Ras GTP
loading and MAPK activation, indicating that the major input
for Ras activation is through PLD2. This set of results also
rationalizes the reduced pAkt levels we observed in statin-
treated cells. Activation of PI3K is achieved by multiple inputs,
and a major input is through activated tyrosine kinases such as
the EGFR, whereas high-strength signaling from Ras-GTP is
required to significantly enhance PI3K activity (21, 48). There-
fore, in statin-treated cells, downregulation of the EGFR and
possibly other GFRs will reduce PI3K activation and hence
Akt activation, because the Ras activation induced by PLD2,
while sufficient to activate Raf, is insufficient to activate PI3K.
In contrast to our results, lovastatin was reported to inhibit
EGF-induced EGFR autophosphorylation; however, this re-
quired very high doses (10 M) that would be expected to
inhibit Rho and Ras prenylation (41). Previous studies have
shown variable effects of statin treatment on MAPK activation,
ranging from stimulation (9, 14, 62) to inhibition (5, 7, 47). One
possible explanation of these diverse results is that cholesterol
depletion by statins has different effects depending on cell type
and experimental conditions (e.g., statin concentration, incu-
bation time, and/or serum starvation/stimulation). Indeed, we
have also observed that caveolin-1 expression is differentially
FIG. 6. Cholesterol depletion stimulates phosphatidic acid production at the plasma membrane. (a) BHK cells were treated with lovastatin for 32 h
in the presence of 10% LPDS. Control cells were cultured in standard growth medium containing 10% DCS. In each case, cells were then labeled with
[3H]palmitate for a further 16 h. Cellular lipids were extracted and resolved by TLC. The graph shows mean phosphatidic acid (PA) level as a percentage
of total phospholipids  SEM for 3 independent experiments. Differences between lovastatin-treated and control cells were assessed using one-way
ANOVA tests, and significant differences are indicated (*, P  0.05). (b) Intact plasma membrane sheets were generated from BHK cells expressing
mGFP-NES-Spo20 and cultured for 48 h in 300 nM lovastatin (LOV) in 10% LPDS or in normal medium containing 10% DCS. Plasma membrane sheets
were labeled with anti-GFP antibody conjugated to 5-nm gold particles. The graph shows the mean number of gold particles/m2 ( SEM). Differences
between lovastatin-treated and control cells were assessed using two-tailed t tests. Significant differences are indicated (***, P  0.001). (c) BHK cells
coexpressing mGFP-NES-Spo20 and mRFP-NES-Spo20 or mRFP were cultured in normal medium containing 10% DCS or 10% LPDS with 300 nM
lovastatin for 48 h. Cells were imaged in a wide-field FLIM microscope. The graph represents the mean fluorescence lifetime of GFP ( SEM).
Differences between lovastatin-treated and control cells were assessed using two-tailed t tests. Significant differences are indicated. BHK cells expressing
mGFP-NES-Spo20 alone cultured in standard growth medium was used to determine initial mGFP lifetime. In this assay a reduction in mGFP lifetime
indicates increased FRET between mGFP and mRFP.
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regulated in HUVECs and BHK cells in response to choles-
terol depletion by lovastatin (K.-J. Cho, unpublished data).
What mechanistic insights into the clinical benefits of statin
treatment flow from these data? ERK activation directly stim-
ulates NO production in many cell lines, including endothe-
lium (8, 19, 64). Therefore, a direct consequence of statin-
induced activation of the PLD2/Ras/MAPK signaling pathway
may be improved endothelial function by increased synthesis of
NO (36). In addition, the lovastatin-induced reduction in
caveolin-1 levels that we have observed in endothelial cells
would be expected to further increase endothelial NO synthe-
sis, since caveolin-1 is a negative regulator of endothelial NO
synthase (eNOS) (18, 44). The Ras/MAPK signal pathway also
regulates expression of bone morphogenetic protein 2 (BMP-
2), which promotes atherosclerotic plaque stability (13, 14, 58).
Our focus throughout this study has been on the ability of
statins to reduce cellular cholesterol levels by a combination of
reduction of LDL-C levels and a direct effect on cellular cho-
lesterol synthesis. It is also clear from Fig. 1 and 2 that the
major effect on cellular cholesterol is mediated at the level of
reduced LDL-C. Very few clinical studies have rigorously ex-
amined cellular cholesterol levels in patients treated with
FIG. 7. Lovastatin-induced EGFR downregulation is blocked by EGFR inhibition. BHK cells were cultured for 48 h in normal medium
containing 10% DCS or 10% LPDS in the presence of lovastatin with or without 0.5 M AG1478. Cell lysates were assayed for total EGFR (a
and b) or ppERK (c and d). The graphs show mean levels of total EGFR or ppERK, relative to levels in AG1478-treated cells grown with lovastatin
under each culture condition,  SEM for 3 independent experiments. Differences between AG1478-untreated and AG1478-treated cells at each
lovastatin concentration were assessed using two-tailed t tests. Significant differences are indicated (*, P  0.05; **, P  0.01; ***, P  0.001).
(e) BHK cells were cultured for 48 h in 10% LPDS plus 300 nM lovastatin or 10% DCS plus 300 nM lovastatin with or without 0.5 M AG1478.
These growth conditions replicate those represented in Fig. 1a, where the presence of DCS maintains normal cell cholesterol levels in the presence
of lovastatin. Control cells were cultured in standard growth medium containing 10% DCS. Total Ras-GTP levels were measured. The graphs show
means  SEM of results from 3 independent experiments. Differences between lovastatin-treated and control cells were assessed using one-way
ANOVA tests. Significant differences are indicated (**, P  0.01).
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statins; however, there are reports of significantly reduced
erythrocyte and platelet cholesterol levels in statin-treated pa-
tients (32, 40). In these studies, the extent of cellular choles-
terol depletion was similar to that achieved in our model in
vitro system.
In summary, our results demonstrate that while therapeutic
levels of lovastatin do not inhibit protein prenylation, choles-
terol depletion induced by lovastatin promotes activities of
PLD2, Ras, and MAPK by possible perturbation of cholesterol-
sensitive nanodomains. Thus, our study strongly suggests that
modulation of cholesterol-dependent membrane organization
plays a major role in statin action and that certain pleiotropic
“cholesterol-independent” effects of statins are, in fact, on
target cholesterol-dependent effects.
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